Did you know Zepbound and Mounjaro both have tirzepatide as their active ingredient1? Zepbound is for weight loss, while Mounjaro treats type 2 diabetes1. This makes us wonder: which is better for weight management? Let’s look at what makes Zepbound and Mounjaro different to help you decide.
Key Takeaways
- Zepbound and Mounjaro both contain the active ingredient tirzepatide, a GLP-1 receptor agonist.
- Zepbound is FDA-approved for weight loss, while Mounjaro is approved for type 2 diabetes treatment.
- Both medications are once-weekly injectable prescriptions with similar dosage ranges.
- Zepbound may lead to up to 20% weight loss in a year, while Mounjaro can also provide weight loss benefits.
- Common side effects for both include gastrointestinal issues like nausea, vomiting, and diarrhea.
Understanding Tirzepatide: The Common Active Ingredient
Tirzepatide is found in both Zepbound and Mounjaro. It’s a key ingredient to grasp. This compound works as a dual-action agent, targeting both GIP and GLP-1 receptors2. It helps manage blood sugar, reduces hunger, and slows down stomach emptying. This leads to better weight control2.
How Tirzepatide Works in the Body
Tirzepatide acts like the body’s natural GLP-1 and GIP hormones. These hormones are vital for blood sugar and hunger control3. Unlike other drugs, tirzepatide targets both receptors. This might make it more effective in controlling blood sugar and aiding in weight loss3.
Dual GIP/GLP-1 Receptor Mechanism
Tirzepatide’s ability to activate both GIP and GLP-1 receptors is its strength2. The GIP action boosts insulin release, while the GLP-1 action slows stomach emptying and reduces hunger2. This dual effect improves blood sugar control and leads to more weight loss than single-receptor drugs3.
“Tirzepatide’s dual-action on GLP-1 and GIP receptors makes it unique among injectable diabetes and weight loss medications.”
FDA Approvals and Primary Uses
Mounjaro (tirzepatide) got FDA approval in May 2022 for type 2 diabetes4. Zepbound (tirzepatide) was approved in November 2023 for weight loss in adults with obesity or overweight4. Both are used with diet and exercise. Mounjaro is also used off-label for weight loss4.
Zepbound is for treating obesity in adults, not just diabetes4. Mounjaro is for diabetes, but weight loss is a side effect4.
Ozempic (semaglutide) helps manage blood sugar in type 2 diabetes patients4. It also helps with heart disease risk. Tirzepatide was better at weight loss than semaglutide, with users losing about 12 pounds more4.
| Medication | FDA Approval | Primary Use | Cost per Month (without insurance) |
| Zepbound | November 2023 | Weight loss and management | $1,060 |
| Mounjaro | May 2022 | Type 2 diabetes treatment | $1,020 to $1,200 |
| Ozempic | Not specified | Type 2 diabetes management | $850 to $1,000 |
Zepbound led to 47% more weight loss than Wegovy5. At 72 weeks, Zepbound caused a 20.2% weight loss, while Wegovy caused 13.7%5. More people on Zepbound lost at least 25% of their body weight than those on Wegovy5.
Ozempic vs. Wegovy vs. Mounjaro vs. Zepbound: What’s the difference?
Tirzepatide (Zepbound) is the only FDA-approved dual GIP and GLP-1 receptor agonist for obesity5. It helps adults with obesity or overweight with weight-related medical problems lose weight and keep it off, with diet and exercise5.
“Medications like Zepbound, Mounjaro, and Ozempic are typically prescribed for individuals with a body mass index (BMI) of 30 or higher (27 or higher with weight-related medical conditions), and are contraindicated for individuals with certain medical histories like pancreatitis or thyroid cancer.”
GLP-1 agonists can cause pancreatitis, pancreatic cancer, thyroid tumors, and slow digestion4. Doctors often check blood work to see how the body reacts4.
It’s important to talk to a doctor before starting weight loss medications45. They consider medical history, allergies, current medications, pregnancy status, and insurance45.
Zepbound: Dedicated Weight Loss Medication
Zepbound is a new weight loss drug making big waves in healthcare6. It’s an injectable that uses tirzepatide to help people lose weight in a big way7.
Dosing Schedule and Administration
Zepbound is given as a weekly subcutaneous injection, usually in the stomach, thigh, or upper arm7. It starts at 2.5 milligrams and can go up to 15 milligrams. Most people take 5, 10, or 15 milligrams7.
Expected Weight Loss Results
Studies show Zepbound leads to impressive weight loss7. People without diabetes lost 18% of their body weight on the 15-milligram dose7. Those with type 2 diabetes lost 12%78.
Zepbound is more effective than some other GLP-1 drugs68. It beats semaglutide (Ozempic and Wegovy) in weight loss, especially at higher doses68.
People using Zepbound will notice it works fast, often in the first week6. It helps with hunger, cravings, and feeling full in 6 to 8 weeks6.
Mounjaro: Diabetes Treatment with Weight Loss Benefits
Mounjaro is a new medication mainly for type 2 diabetes. But it does more than just control blood sugar – it helps with weight loss too9.
This medication is given once a week. It works by acting on two receptors, GLP-1 and GIP. This action helps control blood sugar and leads to weight loss in studies9. People on the highest dose saw their blood sugar levels drop by 2% in 40 weeks9.
Even though it’s not approved for weight loss, Mounjaro has shown to help with it. Studies show it can lead to a 15-20% weight loss over 72 weeks. This is when used with a diet and more exercise10.
Mounjaro’s success in controlling blood sugar and weight comes from its unique action. It targets GLP-1 and GIP receptors. This leads to better blood sugar control and weight loss in people with diabetes9.
As a treatment for type 2 diabetes, Mounjaro is a hopeful solution. It tackles both blood sugar and weight issues. This makes it a great choice for doctors and patients9.
Zepbound vs Mounjaro: Key Differences and Similarities
Zepbound and Mounjaro are two popular weight loss medications. They both have tirzepatide, but they are used differently. Zepbound is for weight loss in adults with a high BMI, while Mounjaro is mainly for type 2 diabetes11.
Prescription Requirements
Zepbound is for adults with a BMI of 30 or higher. It’s also for those with a BMI of 27 or higher and weight-related conditions like high blood pressure or type 2 diabetes12. Mounjaro is mainly for type 2 diabetes but is sometimes used for weight loss too11.
Treatment Duration Considerations
Both Zepbound and Mounjaro may need to be taken for a long time. This is because weight can come back or blood sugar levels can rise again when stopping13. Doctors will decide how long to take these medications based on each person’s needs11.
| Medication | List Price | Weight Loss Results | Savings Programs |
| Zepbound | $1,059.87 per month13 | Average weight loss of 18.4% of body weight after a 72-week trial with tirzepatide, with those on tirzepatide doses of 10 mg or 15 mg losing about 48 pounds on average13. | The Zepbound Savings Card offers those with commercial insurance the opportunity to pay $25 for a one- to three-month prescription fill or $550 for a one-month prescription, saving up to $1,800 per calendar year until the end of 202413. |
| Mounjaro | $1,023.04 per month13 | Significant reduction in HbA1c levels for individuals with type 2 diabetes, with many experiencing weight loss as a secondary benefit11. | No specific savings program mentioned. |
Zepbound and Mounjaro can cause nausea, diarrhea, and upset stomach13. Zepbound users might also get injection site reactions, fatigue, and hair loss13. Serious side effects like stomach problems and depression have been reported13. Doctors should watch for these and adjust treatment plans as needed11.
Choosing between Zepbound and Mounjaro depends on your health goals and medical history. Your doctor will help you decide. Regular check-ups and personalized plans are key to success11.
Common Side Effects and Safety Profiles
Zepbound and Mounjaro can cause side effects like nausea, diarrhea, and vomiting14. They may also lead to constipation, abdominal pain, and hair loss14. Rare but serious issues include kidney injury, gallbladder disease, and pancreatitis14.
Both drugs can cause low blood sugar when used with insulin14. It’s crucial to watch for these signs and talk to your doctor14.
| Zepbound | Mounjaro |
| Nausea, diarrhea, vomiting, constipation, abdominal pain, injection site reactions, fatigue, hair loss | Nausea, diarrhea, vomiting, constipation, abdominal pain |
| Rare but serious: acute kidney injury, gallbladder disease, pancreatitis, depression, suicidal ideation | Rare but serious: acute kidney injury, gallbladder disease, pancreatitis |
| Potential hypoglycemia when used with insulin or insulin secretagogues | Potential hypoglycemia when used with insulin or insulin secretagogues |
Patients should know about these tirzepatide side effects and talk to their doctors14. It’s key to manage gastrointestinal issues and other adverse reactions for safety14.
“Both Zepbound and Mounjaro are powerful medications that can offer significant benefits, but it’s essential to be aware of the potential side effects and work closely with healthcare providers to manage them effectively.”
Cost Comparison and Insurance Coverage
The prices of Zepbound and Mounjaro are close. Mounjaro costs about $1,023.04 for a month’s supply15. Zepbound is a bit more, at $1,059.87 per month15. Both are around $1,000 a month without insurance15.
Zepbound might cost around $550 a month for those without insurance, which is a big drop from the list price15. Ozempic, another GLP-1 receptor agonist, is a bit cheaper, costing between $850-$1,000 a month before insurance15.
Savings Programs and Financial Assistance
Both Mounjaro and Zepbound have savings programs. These can lower costs to as little as $25 for those with insurance15. This is a big help, especially for those with high deductibles or limited budgets.
Medicare and Private Insurance Considerations
But, these savings might not be available for everyone. People with state or federal insurance, like Medicare, might face different costs16. Private insurance can also vary, with Mounjaro possibly being covered more due to its diabetes use17.
The real cost for patients depends on their insurance, pharmacy, and location. Always talk to your healthcare and insurance providers to find out what help is available for Zepbound and Mounjaro16.
Clinical Trial Results and Effectiveness
Clinical trials have shown tirzepatide’s impressive weight loss results. A study found that those taking tirzepatide lost 20% or more of their weight after 72 weeks18. In another trial, participants lost an extra 5% of their weight after 36 weeks, reaching 25% overall weight loss18.
Tirzepatide’s dual-binding effect makes it more effective than other drugs like semaglutide18. The study also stressed the need for lifestyle changes with weight loss medications18. It noted that obesity is chronic and relapsing, making medications like tirzepatide treatments, not cures18.
Tirzepatide also shows great results in managing type 2 diabetes. Clinical trials have shown Mounjaro to be more effective than other GLP-1 medications in improving blood sugar levels18. The SURMOUNT-OSA trial found that tirzepatide reduced apnea-hypopnea index by up to 62.8% in participants with obstructive sleep apnea19.
Studies have shown Zepbound and Mounjaro to be better than single-receptor agonists like semaglutide in weight loss20. Patients on the highest dose of Zepbound lost about 21% of their body weight over 72 weeks20. Those on tirzepatide lost more weight each month than those on semaglutide, with averages of 5.9% after 3 months, 10.1% after 6 months, and 15.3% after 12 months20.
These results highlight the significant weight loss and diabetes management outcomes with tirzepatide-based medications. As research continues, we can expect more advancements in treating obesity and related metabolic conditions.
Availability and Supply Chain Issues
The demand for tirzepatide-based drugs like Zepbound and Mounjaro has caused big supply chain problems21. About 1 in 8 Americans have tried these drugs for weight loss or diabetes21. The number of patients in the U.S. using these drugs is estimated to be up to 2 million21. The FDA says the two-year shortage of tirzepatide is over21, but making enough is still a big challenge.
Eli Lilly, the maker of Zepbound and Mounjaro, expects shortages to last into 202421. Patients might face delays in getting their prescriptions filled. Some might need to try other drugs or compounded versions when they can’t get what they need21.
Patients and healthcare providers are getting frustrated and confused21. Pharmacists have gotten many calls from worried patients and doctors after the shortage ended21. Some pharmacists have had to help patients because they can’t get the drugs they need21. The FDA warns that there might be more supply problems as products move through the system21.
Drugmakers are being asked to make more to avoid future shortages21. The compounding industry wants a new plan to help during shortages21. The Alliance for Pharmacy Compounding is worried about patients switching to commercial products21.
Eli Lilly is trying to make Zepbound affordable, offering single-use vials at a lower price than pens21. Patients stress the need for these drugs to stay healthy and improve their lives21. They face big health problems like insulin resistance and joint pain because of their weight21.
The supply chain problems are also affecting pharmaceutical companies’ finances and operations. Mounjaro’s third-quarter sales were $3.11 billion, less than expected22. Zepbound’s sales in the same quarter were $1.26 billion, also less than expected22. Analysts say about 20% of the revenue misses were due to “destocking”22.
Eli Lilly has spent $10 billion to $15 billion to increase manufacturing for injectable drugs in one year22. The demand for these drugs has been higher than supply for two years22. The company is investing in its website for telehealth and home delivery to help patients get the drugs they need22.
“The FDA notice mentioned that prescribers might encounter intermittent localized supply disruptions as products move through the supply chain.”21
As the healthcare industry deals with these supply chain issues, it’s important for everyone to work together. This ensures patients always have access to these essential medications.
Who Should Consider Each Medication
Zepbound and Mounjaro are two weight loss medications that are getting a lot of attention. Zepbound is approved by the FDA for weight loss and managing weight over time. It’s for adults with a BMI of 30 or higher, or those with a BMI of 27 or higher who have conditions like high blood pressure23.
Mounjaro is mainly for treating type 2 diabetes but also helps with weight loss. It’s a good option for people who have trouble managing their weight and diabetes23.
Medical Requirements and Restrictions
It’s important to know that Zepbound and Mounjaro aren’t for everyone. They’re not recommended for people with pancreatitis or severe stomach problems. Also, those with kidney issues might not be able to take these medications23.
Lifestyle Considerations
Choosing the right medication is just the first step. Successful weight loss and management need a big-picture approach. This includes eating fewer calories and exercising more. Patients should be ready for long-term treatment and willing to make lifestyle changes for the best results23.
Deciding between Zepbound and Mounjaro should be a team effort. A healthcare provider will look at your medical history, goals, and health to pick the best option for you23.
| Medication | Zepbound | Mounjaro |
| Indication | Weight loss and long-term weight management | Type 2 diabetes management |
| BMI Requirement | ≥30 or ≥27 with weight-related conditions | No specific BMI requirement |
| Contraindications | History of pancreatitis, severe gastrointestinal conditions, kidney problems | History of pancreatitis, severe gastrointestinal conditions, kidney problems |
| Lifestyle Changes | Reduced-calorie diet, increased physical activity | Reduced-calorie diet, increased physical activity |
Zepbound and Mounjaro are medications that use tirzepatide to help with weight loss. Zepbound is approved for weight loss, while Mounjaro is mainly for diabetes . Certain medical conditions, like pancreatitis, make these medications not suitable for everyone23. But, both need a big-picture approach that includes diet and exercise for them to work well23.
Conclusion
Zepbound and Mounjaro are promising for those looking to manage their weight effectively24. They work by targeting two key receptors in the body, leading to notable weight loss24. Zepbound is made for weight loss.
Choosing between Zepbound and Mounjaro depends on your health, insurance, and what you hope to achieve25. It’s important to talk to your doctor about these options24. They can help you decide and make sure you’re following the right treatment plan24.
Both drugs can cause stomach problems and have a warning about thyroid cancer24. This highlights the need for careful patient evaluation before starting treatment24.
More research on tirzepatide could lead to better weight management and metabolic health in the future26. A tailored approach, considering your unique needs and doctor’s advice, is key to lasting weight management success26.
FAQ
What is the difference between Zepbound and Mounjaro?
Zepbound and Mounjaro both have tirzepatide as their active ingredient. Zepbound is for weight loss, while Mounjaro treats type 2 diabetes. They differ in side effects, cost, and insurance coverage.
How does tirzepatide work in the body?
Tirzepatide acts like GLP-1 and GIP hormones. It slows digestion and reduces hunger. This makes tirzepatide special for diabetes and weight loss treatments.
What are the FDA approvals and primary uses of Zepbound and Mounjaro?
Mounjaro was approved in 2022 for type 2 diabetes. Zepbound got approval in 2023 for weight loss in adults. Mounjaro can also be used off-label for weight loss.
How are Zepbound and Mounjaro administered and what are the typical dosages?
Both are injected weekly under the skin. Zepbound starts at 2.5mg and goes up to 15mg. Mounjaro also starts at 2.5mg and goes up to 15mg.
What are the key differences and similarities between Zepbound and Mounjaro?
Zepbound is for weight loss, while Mounjaro is for type 2 diabetes. But they both have tirzepatide and are given in the same way.
What are the common side effects associated with Zepbound and Mounjaro?
Both can cause nausea, diarrhea, vomiting, and constipation. Zepbound might also lead to injection site reactions and hair loss. Rare but serious side effects include kidney injury, gallbladder disease, and pancreatitis.
How do the costs and insurance coverage compare for Zepbound and Mounjaro?
Both cost around $1,060 a month. But, costs can change based on insurance and where you buy it. Eli Lilly offers savings programs, but they don’t cover everyone.
How effective are Zepbound and Mounjaro in clinical trials?
Mounjaro has shown better blood sugar control than other GLP-1 meds. Zepbound trials have seen big weight loss, up to 20% of body weight. Both have done better than single-receptor agonists in studies.
What are the availability and supply chain issues with Zepbound and Mounjaro?
Both have faced shortages since approval. Eli Lilly expects these shortages to last into 2024. Patients might face delays in getting their meds, and other options might be considered.
Who should consider taking Zepbound or Mounjaro?
Zepbound is for adults with a BMI of 30 or higher, or 27 with a weight-related condition. Mounjaro is for type 2 diabetes. Neither is recommended for pregnant women or those with pancreatitis history.